Editorial: Mechanistic studies of genome integrity, environmental health, and cancer etiology

Shan Yan1*, Jianjun Zhao2*, Michael Kemp3* and Robert W. Sobol4*†

1Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States, 2Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States, 3Department of Pharmacology and Toxicology, Wright State University, Dayton, OH, United States, 4Mitchell Cancer Institute and Department of Pharmacology, University of South Alabama, Mobile, AL, United States

KEYWORDS

genome integrity, environmental health, cancer etiology, DNA repair, DNA damage response

Editorial on the Research Topic
Mechanistic studies of genome integrity, environmental health, and cancer etiology

Genomic DNA in all cell types is exposed to insults from endogenous sources, such as oxidative stress, as well as exogenous sources, including environmental genotoxins and anti-cancer therapeutics. Deficiencies in genome integrity maintenance pathways have been implicated in the etiology of cancer and other disease states. To mitigate the debilitating genomic lesions, cells have evolved many different pathways to sense, repair, and signal in response to such challenges. Research studies focused on understanding genome integrity mechanisms have utilized a variety of model organisms and cutting-edge technologies at the molecular, cellular, organismal, and ecological levels. Mechanistic studies that help define the process of genome integrity maintenance, the impact of such mechanisms on environmental health, and their role in cancer etiology are highly significant and have led to new ways of diagnosing and treating cancers and other human diseases. Because of the many advances in this area of research over the past few years, this Research Topic intends to provide the latest insights on the field of genome integrity and to discuss the trends of current and future studies aimed at improving our understanding of disease pathogenesis and treatment. Here, we provide an editorial to summarize these seven research articles and two review articles.

Oxidative stress is a cellular process that is aggravated with aging, by consumption of certain diets, or under chemotherapeutic treatment, and results in damage to the DNA of the cells (Pizzino et al., 2017). Oxidative DNA damage is mainly repaired through the base excision repair (BER) pathway (Maynard et al., 2009). Here, Burchat et al. identified a novel function of human 8-oxoguanine DNA glycosylase-1 (OGG1) beyond its conventional DNA repair function as an initiator of BER-mediated DNA repair...
related to an increase in tissue mitochondrial content (Figure 1). Further, they reported for the first time that OGG1-mediated obesity resistance in both the Agouti obese (Ay/a) mouse model and the diet-induced obesity (DIO) model requires maternal transmission of the hOGG1 transgene. This novel finding of a critical role for OGG1 in modulating energy balance will open a new research field to connect the conventional DNA repair machinery with mitochondrial function in tissues.

Whereas the BER protein Apurinic/Apyrimidinic endonuclease 2 (APE2) has been implicated in the Ataxia-telangectasia and Rad3 related (ATR)-Checkpoint kinase 1 (Chk1) DNA damage response (DDR) pathway in the Xenopus system (Willis et al., 2013; Wallace et al., 2017; Lin et al., 2018; Lin et al., 2021), Hossain et al. here provide evidence in pancreatic cancer cells that APE2 is a general regulator of the ATR-Chk1 DDR in response to different stress conditions including oxidative stress, DNA replication stress, and DNA double-strand breaks (DSBs) (Figure 1). A small molecule compound named Celastrol was reported as the first-known APE2 inhibitor that specifically impairs APE2 exonuclease activity by inhibiting its binding to single-stranded DNA (ssDNA). Sensitizing pancreatic cancer cell viability to chemotherapy drugs via APE2-knockdown or exposure to the APE2 inhibitor Celastrol supports the idea that targeting APE2 can provide novel insight into new cancer treatments.

In addition to its well-known checkpoint function in the nucleus, cytoplasmic ATR is converted from trans-into a cis-isomeric conformation at the Ser428-Pro429 motif within the BH3 domain in a Pn1/DAPK1-regulated manner to suppress apoptosis in mitochondria following ultraviolet (UV) damage (Hilton et al., 2015). Biswas et al. provides the structural basis of the mitochondrial isoform of ATR using a mass spectrometry-
based foot printing approach (Figure 1). Two biotin-modified residues K459 and K469 within the BH3 domain of cis-ATR are not accessible in trans-ATR, suggesting a conformation change around the BH3 domain between cis- and trans-ATR. Furthermore, cis-ATR with the accessible BH3 domain, but not trans-ATR, is able to associate with tBid. These findings suggest that the isomerization-induced structural changes of mitochondrial specific cis-ATR are essential for its role in cell survival and the DDR pathway.

In recent years, PARP inhibitors (PARPi) targeting PARP1 and PARP2 have been developed as a novel targeted cancer therapeutic due to their roles in DNA damage repair (Javle and Curtin, 2011; Lord and Ashworth, 2017). But many other members of the PARP protein family with a catalytic domain similar to PARP1 and PARP2 are understudied regarding their function on DNA damage repair and tumor initiation (Jubin et al., 2016). Richard et al. comprehensively reviews the current knowledge of the potential functions of PARP isoforms 4 and 6-16 and discusses the roles these proteins may play in DNA damage repair and as targets for cancer therapeutics (Figure 1). This review also points out the future research directions and further research needs to be conducted.

Following the initial treatment of radiation and chemotherapy, cancer recurrence and acquired resistance are major problems in the clinic. Using pairs of same patient-derived primary and recurrent oral cancer cell lines, Wang et al. identified PARP1 upregulation in the recurrent but not primary oral tumor cells and such PARP1 upregulation was augmented by the chemotherapy drugs cisplatin and 5-fluorouracil (Figure 1). Ectopic overexpression of PARP1 rendered the primary cancer cells resistant to chemotherapy drugs and PARP1 inhibitors sensitized recurrent cancer cells to chemotherapy drugs in vitro and in vivo. Thus, PARP1 upregulation in recurrent oral cancers suggests that targeting PARP1 can be expanded to recurrent oral cancer treatment.

Y-box binding protein 1 (YBX1, YB-1) is a cold shock domain protein that binds both DNA and RNA and is implicated in numerous cellular processes including transcription, translation, mRNA packaging, pre-mRNA splicing and DNA repair. The involvement of YB-1 in these myriad mechanisms are mediated via numerous protein-protein interactions. Similarly, its role in DNA repair involves interactions with MSH2, DNA polymerase delta, Ku80 and WRN (Gaudreault et al., 2004), RAD21 (Panigrahi et al., 2012), BARD1 and BRCA1 (Woods et al., 2012). Recently, YB-1 was identified among proteins proximal to trapped PARP1 (Krstev et al., 2022). This new report by Naumenko et al. provides more detail on the interaction between YB-1 and PARP1 and the role of YB-1 in regulating poly-ADP-ribose (PAR) synthesis via the interaction between the disordered YB-1 C-terminal domain (CTD) and PAR (Figure 1). Overall, they suggest that YB-1 CTD-like domains may be considered PAR "readers" similar to other known PAR-binding modules.

Nucleotide excision repair (NER) plays an essential role in the removal of bulky DNA lesions induced by UV radiation and other genotoxins. Though biochemical studies have defined the NER mechanism on naked DNA in vitro, the packaging of DNA into histones and higher order chromatin structures in the cell in vivo likely impacts the ability of the NER machinery to do its job. In this perspective, Li et al. provides a comprehensive summary of how different post-translational modifications to histones by specific classes of enzymes impact NER function in vivo (Figure 1).

Proteins of the mismatch repair (MMR) pathway function to correct replication errors including base-base mispairs and small insertion/deletion mispairs (Jiricny, 2006; Li, 2008; Fishel, 2015). In addition, the MMR pathway recognizes DNA damage induced mispairs to trigger apoptosis, such as that induced by the O6-methylguanineethymidime mispairs that arises after exposure to SN1 alkylators (Fu et al., 2012; Soll et al., 2017; Fuji et al., 2022). While the core proteins for MMR have been well defined (Modrich, 2016), additional proteins that complex with MMR proteins and that may regulate the MMR pathway are anticipated. Here, Miller et al. identified Rad5 (Saccharomyces cerevisiae) as an Mlh1 and Msh2 interacting protein (Figure 1). Further, they show that the human counterparts of Rad5 (HLTF and SHPRH) interact with MSH2 and MLH1, respectively. This novel finding will form the basis for future studies to uncover the detailed functional role of these and other MMR interacting proteins.

In response to constant endogenous and/or exogenous sources of DNA damaging agents, it is essential for cells to maintain the stability of the 16.5 kb mitochondrial DNA (mtDNA) in humans, in addition to the nuclear genome (Copeland and Longley, 2014). Sharma et al. here reported and characterized the interaction between the BER protein Nei-like DNA Glycosylase 1 (NEIL1) and mitochondrial transcription factor A (TFAM) which requires the presence of DNA/RNA (Figure 1). Interestingly, NEIL1 is necessary for efficient transcription by TFAM upon alkylating agent induced DNA damage. The regulation of the NEIL1-TFAM interaction by salt concentrations, protein availability, nucleic acids, and the presence of DNA damage suggests a transient, dynamic, and functional association to maintain mtDNA stability.

Overall, the research and review articles in this Research Topic have identified and/or characterized several distinct mechanisms of how cells respond to environmental factors, such as diet, UV, and chemotherapy drugs, and how nuclear genome and epigenome integrity and mitochondria stability are maintained (Figure 1). Future studies in the field to consider include 1) how different environmental factors including but not limited to air pollutants, viruses, and pesticides affect genomic and/or epigenomic integrity; 2) how distinct DNA repair and DDR pathways sense and signal environmental and intrinsic insults; 3) how cutting-edge omics technologies are applied to...
better understand genome integrity and public health; and 4) how our novel knowledge in genome/epigenome integrity provides better strategies for cancer therapeutics.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Funding

SY laboratory is supported by grants from the NIH/NCI (R01CA225637, R01CA263897, and R01CA251141–subaward) and the NIH/NIAMS (R21ES032966) and funds from UNC Charlotte. JZ laboratory is supported by grants from the NIH/NCI (R01CA251141) and the NIH/NINDS (R01NS124081), V Foundation Scholar Award, ASH bridge award, and two Velosano Grants. MK laboratory is supported by grants from the National Institute of General Medical Sciences (GM130583), Ohio Cancer Research Associates (#5020), the Veterans Administration (I01CX002241). RWS is an Abraham A. Mitchell Distinguished Investigator. Research in the Sobol lab on DNA repair, the analysis of DNA damage and the impact of genotoxic exposure is funded by grants from the NIH (ES029518, CA148629, ES014811, ES028949, CA238061, CA236911, AG069740 and ES032522), from the NSF (NSF-1841811) and a grant from the DOD (GRANT1199891, DURIP-Navy). Support is also provided by grants from the Breast Cancer Research Foundation of Alabama, from the Abraham A. Mitchell Distinguished Investigator Fund, and from the Mitchell Cancer Institute Molecular & Metabolic Oncology Program Development fund (to RWS).

Acknowledgments

We thank all the authors and reviewers who made contributions to this exciting Research Topic.

Conflict of interest

RWS is a scientific consultant for Canal House Biosciences, LLC. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Copeland, W. C., and Longley, M. J. (2014). Mitochondrial genome maintenance in health and disease. DNA Repair (Amst) 19, 190–198. doi:10.1016/j.dnarep.2014.03.010

Fischel, R. (2015). Mismatch repair. J. Biol. Chem. 290, 26395–26403. doi:10.1074/jbc.r115.660142

Fu, D., Calvo, J. A., and Samson, L. D. (2012). Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat. Rev. Cancer 12, 104–120. doi:10.1038/nrc3185

Fujii, S., Sobol, R. W., and Fuchs, R. P. (2022). Double-strand breaks: When DNA repair events accidentally meet. DNA Repair (Amst) 112, 103303. doi:10.1016/j.dnarep.2022.103303

Gaudreault, I., Guay, D., and Lebel, M. (2004). YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res. 32, 316–327. doi:10.1093/nar/gkh170

Hilton, B. A., Li, Z., Musich, P. R., Wang, H., Cartwright, B. M., Serrano, M., et al. (2015). ATR plays a direct antiapoptotic role at mitochondria, which is regulated by prolyl isomerase Pin1. Mol. Cell 60, 35–46. doi:10.1016/j.molcel.2015.08.008

Javle, M., and Curtin, N. J. (2011). The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer 105, 1114–1122. doi:10.1038/bjc.2011.382

Jiricny, J. (2006). The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 7, 335–346. doi:10.1038/nrm1907

Jubin, T., Kadam, A., Jarwala, M., Bhatt, S., Sutariya, S., Gani, A. R., et al. (2016). The PARP family: Insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival. Cell Prolif. 49, 421–437. doi:10.1111/cpr.12268

Krastev, D. B., Li, S., Sun, Y., Hicks, A. J., Hoslett, G., Weekes, D., et al. (2022). The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nat. Cell Biol. 24, 62–73. doi:10.1038/s41556-021-00807-6

Li, G. M. (2008). Mechanisms and functions of DNA mismatch repair. Cell Res. 18, 85–98. doi:10.1038/cr.2007.115

Lin, Y., Bai, L., Cupello, S., Hossain, M. A., Deem, B., McLeod, M., et al. (2018). APE2 promotes DNA damage response pathway from a single-strand break. Nucleic Acids Res. 46, 2479–2494. doi:10.1093/nar/gky020

Lin, Y., McMahon, A., Driscoll, G., Bullock, S., Zhao, J., and Yan, S. (2021). Function and molecular mechanisms of APE2 in genome and epigenome integrity. Mutat. Res. Rev. Mutat. Res. 787, 108347. doi:10.1016/j.mrrr.2020.108347

Lord, C. J., and Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152–1158. doi:10.1126/science.aam7344

Maynard, S., Schurman, S. H., Harhoe, C., de Souza-Pinto, N. C., and Bohr, V. A. (2009). Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 30, 2–10. doi:10.1093/carcin/bgpn250
Modrich, P. (2016). Mechanisms in E. coli and human mismatch repair (nobel lecture). Angew. Chem. Int. Ed. Engl. 55, 8490–8501. doi:10.1002/anie.201601412

Panigrahi, A. K., Zhang, N., Otta, S. K., and Pati, D. (2012). A cohesin-RAD21 interactome. Biochem. J. 442, 661–670. doi:10.1042/BJ20111745

Pizzino, G., Irvera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., et al. (2017). Oxidative stress: Harms and benefits for human health. Oxid. Med. Cell. Longev. 2017, 8416763. doi:10.1155/2017/8416763

Soll, J. M., Sobol, R. W., and Mosammaparast, N. (2017). Regulation of DNA alkylation damage repair: Lessons and therapeutic opportunities. Trends biochem. Sci. 42, 206–218. doi:10.1016/j.tibs.2016.10.001

Wallace, B. D., Berman, Z., Mueller, G. A., Lin, Y., Chang, T., Andres, S. N., et al. (2017). APE2 ZF-GRF facilitates 3’-5’ resection of DNA damage following oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 114, 304–309. doi:10.1073/pnas.1610011114

Willis, J., Patel, Y., Lentz, B. L., and Yan, S. (2013). APE2 is required for ATR-Chk1 checkpoint activation in response to oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 110, 10592–10597. doi:10.1073/pnas.1301445110

Woods, N. T., Mesquita, R. D., Sweet, M., Carvalho, M. A., Li, X., Liu, Y., et al. (2012). Charting the landscape of tandem BRCT domain-mediated protein interactions. Sci. Signal. 5, rs6. doi:10.1126/scisignal.2002255